Circulating Galectin-3 in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction Treated with Mild Hypothermia: A Biomarker Sub-Study of the SHOCK-COOL Trial.
Wenke ChengGeorg FuernauSteffen DeschAnne FreundHans-Josef FeistritzerJanine PössChristian BeslerPhilipp LurzPetra BüttnerHolger ThielePublished in: Journal of clinical medicine (2022)
MTH has no effect on Gal-3 levels in patients with CS complicating AMI compared to the control group. In addition, Gal-3 is a relatively stable biomarker, independent of age, sex, and BMI, and Gal-3 levels at admission might predict the risk of 30-day all-cause mortality.